FDMT 4D Molecular Therapeutics Inc

Price (delayed)

$17.08

Market cap

$883.09M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.44

Enterprise value

$621.67M

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector ...

Highlights
The company's equity has surged by 175% YoY and by 95% QoQ
FDMT's quick ratio has soared by 111% QoQ and by 80% YoY
The company's net income rose by 4.8% YoY but it fell by 3.7% QoQ

Key stats

What are the main financial stats of FDMT
Market
Shares outstanding
51.7M
Market cap
$883.09M
Enterprise value
$621.67M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.42
Price to sales (P/S)
41.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.4
Earnings
Revenue
$20.45M
EBIT
-$104.56M
EBITDA
-$98.63M
Free cash flow
-$79.44M
Per share
EPS
-$2.44
Free cash flow per share
-$1.61
Book value per share
$12.06
Revenue per share
$0.42
TBVPS
$12.78
Balance sheet
Total assets
$629.88M
Total liabilities
$29.32M
Debt
$14.17M
Equity
$600.56M
Working capital
$519.19M
Liquidity
Debt to equity
0.02
Current ratio
32.65
Quick ratio
32.06
Net debt/EBITDA
2.65
Margins
EBITDA margin
-482.2%
Gross margin
100%
Net margin
-511.2%
Operating margin
-591.1%
Efficiency
Return on assets
-24.8%
Return on equity
-26.7%
Return on invested capital
-65.4%
Return on capital employed
-17%
Return on sales
-511.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FDMT stock price

How has the 4D Molecular Therapeutics stock price performed over time
Intraday
18.61%
1 week
-36.58%
1 month
-25.54%
1 year
-5.27%
YTD
-15.7%
QTD
-18.63%

Financial performance

How have 4D Molecular Therapeutics's revenue and profit performed over time
Revenue
$20.45M
Gross profit
$20.45M
Operating income
-$120.9M
Net income
-$104.56M
Gross margin
100%
Net margin
-511.2%
The company's net margin has surged by 90% YoY but it fell by 5% QoQ
The operating margin has soared by 89% YoY but it has contracted by 9% from the previous quarter
The operating income is down by 7% QoQ and by 6% YoY
The company's net income rose by 4.8% YoY but it fell by 3.7% QoQ

Growth

What is 4D Molecular Therapeutics's growth rate over time

Valuation

What is 4D Molecular Therapeutics stock price valuation
P/E
N/A
P/B
1.42
P/S
41.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.4
4D Molecular Therapeutics's EPS has increased by 28% YoY and by 5% from the previous quarter
The company's equity has surged by 175% YoY and by 95% QoQ
The stock's P/B is 35% below its last 4 quarters average of 2.2
The P/S is 63% lower than the last 4 quarters average of 110.7

Efficiency

How efficient is 4D Molecular Therapeutics business performance
4D Molecular Therapeutics's ROS has soared by 90% YoY but it has decreased by 5% from the previous quarter
The return on equity is up by 41% year-on-year and by 22% since the previous quarter
The ROA has grown by 38% YoY and by 20% from the previous quarter
The return on invested capital rose by 26% since the previous quarter but it has declined by 11% year-on-year

Dividends

What is FDMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FDMT.

Financial health

How did 4D Molecular Therapeutics financials performed over time
4D Molecular Therapeutics's total assets has soared by 158% YoY and by 85% from the previous quarter
FDMT's quick ratio has soared by 111% QoQ and by 80% YoY
The company's debt is 98% lower than its equity
The company's equity has surged by 175% YoY and by 95% QoQ
FDMT's debt to equity has dropped by 71% year-on-year and by 60% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.